Literature DB >> 9129859

Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations.

T G Karrison1.   

Abstract

In the analysis of survival data from clinical trials and other studies, the censoring generally precludes estimation of the mean survival time. To accommodate censoring, Irwin (1949) proposed, as an alternative, estimation of the mean lifetime restricted to a suitably chosen time T. In this article we consider the use of Irwin's restricted mean as an index for comparing survival in different groups, using as an example published data from a randomized clinical trial in patients with primary biliary cirrhosis. Irwin's method, originally based on the actuarial survival estimator, is extended to incorporate covariates into the analysis through the use of piecewise exponential models. For comparing two survival curves, the logrank test is known to be optimal under proportional hazards alternatives. However, comparison of restricted means may outperform the logrank test in situations involving nonproportional hazard rates. We examine the size and power of these two procedures under various proportional and nonproportional hazards alternatives, with and without covariate adjustment. For survival curves that separate early in time the censored data generalization of the Wilcoxon test is known to exhibit high power, and we examine how the comparison of restricted means performs relative to this procedure also.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129859     DOI: 10.1016/s0197-2456(96)00089-x

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  24 in total

Review 1.  North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure.

Authors:  M Eccles; N Freemantle; J Mason
Journal:  BMJ       Date:  1998-05-02

2.  Contrasting treatment-specific survival using double-robust estimators.

Authors:  Min Zhang; Douglas E Schaubel
Journal:  Stat Med       Date:  2012-07-16       Impact factor: 2.373

3.  Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.

Authors:  Niels Neymark; Pilar Lianes; Egbert F Smit; Jan P van Meerbeeck
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity.

Authors:  Sadiya S Khan; Hongyan Ning; John T Wilkins; Norrina Allen; Mercedes Carnethon; Jarett D Berry; Ranya N Sweis; Donald M Lloyd-Jones
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

5.  Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Authors:  Ezra E W Cohen; Theodore G Karrison; Masha Kocherginsky; Jeffrey Mueller; Robyn Egan; Chao H Huang; Bruce E Brockstein; Mark B Agulnik; Bharat B Mittal; Furhan Yunus; Sandeep Samant; Luis E Raez; Ranee Mehra; Priya Kumar; Frank Ondrey; Patrice Marchand; Bettina Braegas; Tanguy Y Seiwert; Victoria M Villaflor; Daniel J Haraf; Everett E Vokes
Journal:  J Clin Oncol       Date:  2014-07-21       Impact factor: 44.544

6.  Are restricted mean survival time methods especially useful for noninferiority trials?

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-02-24       Impact factor: 2.486

7.  Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial.

Authors:  Ryuichiro Doi; Masayuki Imamura; Ryo Hosotani; Toshihide Imaizumi; Takashi Hatori; Ken Takasaki; Akihiro Funakoshi; Hideyuki Wakasugi; Takehide Asano; Shoichi Hishinuma; Yoshiro Ogata; Makoto Sunamura; Koji Yamaguchi; Masao Tanaka; Sonshin Takao; Takashi Aikou; Koichi Hirata; Hiroyuki Maguchi; Koichi Aiura; Tatsuya Aoki; Akira Kakita; Makoto Sasaki; Masahiko Ozaki; Satoru Matsusue; Shunichi Higashide; Hideki Noda; Seiyo Ikeda; Shunzo Maetani; Shigeaki Yoshida
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

8.  Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises.

Authors:  Priyathama Vellanki; Dawn D Smiley; Darko Stefanovski; Isabel Anzola; Wenlan Duan; Megan Hudson; Limin Peng; Francisco J Pasquel; Guillermo E Umpierrez
Journal:  Diabetes Care       Date:  2016-08-29       Impact factor: 19.112

9.  Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.

Authors:  Niels Neymark; Thierry Gorlia; Ines Adriaenssen; Benoit Baron; Martine Piccart
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

10.  Analysis of restricted mean survival time for length-biased data.

Authors:  Chi Hyun Lee; Jing Ning; Yu Shen
Journal:  Biometrics       Date:  2017-09-08       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.